Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Marinus Pharma (MRNS) Tops Q3 EPS by 20c; Reports Cash and Cash Equivalents of $145.1M
November 9, 2021 7:21 AM ESTMarinus Pharma (NASDAQ: MRNS) reported Q3 EPS of ($0.53), $0.20 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $10.11 million versus the consensus estimate of $2.17 million.
For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.
... More